Form 8-K - Current report:
SEC Accession No. 0001193125-24-269398
Filing Date
2024-12-03
Accepted
2024-12-03 07:09:59
Documents
15
Period of Report
2024-12-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d916753d8k.htm   iXBRL 8-K 25964
2 EX-99.1 d916753dex991.htm EX-99.1 30274
6 GRAPHIC g916753g1203044035755.jpg GRAPHIC 3606
  Complete submission text file 0001193125-24-269398.txt   191807

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20241203.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20241203_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20241203_pre.xml EX-101.PRE 11259
17 EXTRACTED XBRL INSTANCE DOCUMENT d916753d8k_htm.xml XML 3628
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 241521054
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)